Squarepoint Ops LLC Trims Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

Squarepoint Ops LLC lowered its position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 17.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 590,510 shares of the company's stock after selling 121,729 shares during the period. Squarepoint Ops LLC owned 0.49% of 10x Genomics worth $8,480,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. Entropy Technologies LP lifted its stake in 10x Genomics by 285.6% in the fourth quarter. Entropy Technologies LP now owns 37,595 shares of the company's stock valued at $540,000 after buying an additional 27,844 shares during the period. SG Americas Securities LLC increased its stake in shares of 10x Genomics by 209.8% in the 4th quarter. SG Americas Securities LLC now owns 73,046 shares of the company's stock valued at $1,049,000 after acquiring an additional 49,468 shares in the last quarter. Alberta Investment Management Corp acquired a new position in shares of 10x Genomics during the 4th quarter valued at $3,206,000. China Universal Asset Management Co. Ltd. bought a new position in 10x Genomics during the fourth quarter worth $326,000. Finally, Barclays PLC boosted its stake in 10x Genomics by 11.7% during the third quarter. Barclays PLC now owns 602,536 shares of the company's stock worth $13,605,000 after acquiring an additional 63,079 shares in the last quarter. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have issued reports on TXG shares. Barclays cut their price target on 10x Genomics from $15.00 to $12.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Wall Street Zen upgraded 10x Genomics from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. JPMorgan Chase & Co. reduced their price target on shares of 10x Genomics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. The Goldman Sachs Group lowered their price objective on shares of 10x Genomics from $7.50 to $6.50 and set a "sell" rating on the stock in a report on Monday, May 12th. Finally, Leerink Partners lowered shares of 10x Genomics from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $25.00 to $12.00 in a research note on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $15.81.

Insider Transactions at 10x Genomics

In related news, insider Benjamin J. Hindson sold 7,485 shares of 10x Genomics stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $8.30, for a total value of $62,125.50. Following the completion of the sale, the insider now directly owns 448,374 shares in the company, valued at $3,721,504.20. The trade was a 1.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Adam Taich sold 4,044 shares of the firm's stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total transaction of $33,565.20. Following the completion of the sale, the chief financial officer now owns 331,588 shares of the company's stock, valued at approximately $2,752,180.40. This trade represents a 1.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 20,872 shares of company stock worth $173,238. 9.39% of the stock is currently owned by company insiders.

10x Genomics Trading Up 3.1%

10x Genomics stock traded up $0.27 during mid-day trading on Wednesday, hitting $8.86. The stock had a trading volume of 2,849,590 shares, compared to its average volume of 2,392,703. The firm's 50 day moving average is $8.52 and its 200 day moving average is $11.95. The firm has a market capitalization of $1.09 billion, a P/E ratio of -5.83 and a beta of 1.94. 10x Genomics, Inc. has a one year low of $6.78 and a one year high of $24.76.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. The firm had revenue of $154.88 million during the quarter, compared to analyst estimates of $131.91 million. 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. 10x Genomics's revenue for the quarter was down 2.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.50) earnings per share. As a group, equities research analysts forecast that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.